The 7 major glutaric acidemia type 1 markets reached a value of USD 530.5 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 947.4 Million by 2035, exhibiting a growth rate (CAGR) of 5.43% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 530.5 Million |
Market Forecast in 2035
|
USD 947.4 Million |
Market Growth Rate (2025-2035)
|
5.43% |
The glutaric acidemia type 1 market has been comprehensively analyzed in IMARC's new report titled "Glutaric Acidemia Type 1 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Glutaric acidemia type 1 (GA-1) is an autosomal recessive condition indicated by a lack of glutaryl-CoA dehydrogenase (GCDH) activity. This causes glutaric acid to accumulate in tissues and be excreted in the urine of affected patients. GCD is involved in the breakdown of the amino acids lysine, hydroxylysine, and tryptophan. The severity of GA-1 varies significantly; some people are just minimally affected, while others experience serious problems. Signs and symptoms typically appear in infancy or early childhood; however, in a small number of cases, the condition manifests itself in adolescence or adulthood. Many babies born with this disease have abnormally large heads (macrocephaly). Affected people may also have difficulties moving and have spasms, jerks, rigidity, or decreased muscular tone. Some GA-1 patients have experienced bleeding in the brain or eyes, which could be misinterpreted as the consequence of child abuse. The illness is primarily diagnosed through neonatal blood spot screening, which identifies high levels of glutaric acid and 3-hydroxyglutaric acid in the urine. The healthcare provider also recommends additional studies, including enzyme examination of cultured fibroblasts, genetic testing for GCDH gene alterations, and screening of blood and cerebrospinal fluid for 3-hydroxyglutaric acid.
The escalating prevalence of mutations in the GCDH gene, which provides instructions for making the enzyme glutaryl-CoA dehydrogenase, is primarily driving the glutaric acidemia type 1 market. In addition to this, the inflating utilization of carnitine supplementation to help in minimizing the accumulation of toxic glutaric acid in the body and improving the outcomes for patients is also creating a positive outlook for the market. Moreover, the rising usage of genetic testing using next-generation sequencing and whole-exome sequencing that can identify mutations in the GCDH gene for definitive diagnosis of GA-1 in individuals with atypical biochemical profiles or late-onset symptoms is further bolstering the market growth. Apart from this, the widespread adoption of dietary therapy, which primarily involves a low-protein diet, specifically restricting the intake of lysine and tryptophan to reduce toxic metabolite buildup and prevent neurological complications, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, since it delivers a functional copy of the GCDH gene, thereby effectively replacing the defective enzyme and mitigating the disease symptoms, is expected to drive the glutaric acidemia type 1 market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the glutaric acidemia type 1 market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for glutaric acidemia type 1 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the glutaric acidemia type 1 market in any manner.
VGM-R02b is an investigational gene replacement therapy designed to address glutaric acidemia type I. The mechanism of action of VGM-R02b involves delivering a functional copy of the GCDH gene to patients' cells, thereby restoring the production of active glutaryl-CoA dehydrogenase enzyme. This restoration enables the proper metabolism of lysine, hydroxylysine, and tryptophan, preventing the accumulation of harmful metabolites and potentially improving clinical outcomes for affected individuals.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current glutaric acidemia type 1 marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
VGM-R02b | Shanghai Vitalgen BioPharma |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Glutaric Acidemia Type 1: Current Treatment Scenario, Marketed Drugs and Emerging Therapies